Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederstatnews.com
STAT
Get the latest updates from STAT directly as they happen.
Follow now 208 followers
Latest posts
Last updated about 7 hours ago
STAT+: Academic groups finalize counterproposal to Trump’s research overhead cuts
about 7 hours ago
A coalition of academic organizations has finalized a proposed alternative to the...
NIH grant cuts, FDA transparency questions, and biotech M&A
about 12 hours ago
On this week’s episode of “The Readout LOUD”: a closer look at...
FDA grants full approval to Moderna’s Covid vaccine for children but limits eligibility
about 14 hours ago
Moderna’s Covid-19 vaccine for children has been given full Food and Drug...
STAT+: FDA won’t pay 2024 bonuses to workers who are getting laid off
about 17 hours ago
You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about...
STAT+: FDA publishes rejection letters sent to drugmakers, with a big caveat
about 18 hours ago
The Food and Drug Administration on Thursday published more than 200 letters...
STAT+: Brawl over Eylea gets biosimilar industry’s attention
about 18 hours ago
Hello! Today, we talk about a cool experimental enzyme therapy, observe more...
STAT+: Pharmalittle: We’re reading about Regeneron’s patent maneuvers, FDA rejection letters, and lots more
about 18 hours ago
Top of the morning to you. And a fine one it is...
STAT+: Eyes on Soleno’s Prader-Willi drug launch
about 21 hours ago
This is the online version of Adam’s Biotech Scorecard, a subscriber-only newsletter...
STAT+: Renasant Bio, an underdog in the race to develop kidney disease therapies, raises $54.5 million
about 21 hours ago
With investors and drugmakers increasingly eyeing the kidney disease space, a new...
Opinion: STAT+: How to evaluate GLP-1s and Medicare costs? Here’s one idea
about 23 hours ago
Today, more than 40% of adults over 60 are considered obese, fueling...
MAHA’s European food envy is full of contradictions
about 23 hours ago
The idea of making the U.S. more like Europe is anathema to...
STAT+: How Regeneron, maker of a best-selling eye drug, is using patent tactics to try to thwart competition
about 23 hours ago
A court battle between two of the nation’s largest biotechs — Regeneron...